APOE Knockout THP-1 Cell Pool

Hot Products

undefined
undefined
+
  • undefined
  • undefined

Number:

LM01300130203

Product ID: LM01300130203

Market price

Selling Price:  ¥ 5499

Quantity
-
+

Stock surplus

Contact us to order

Antibody custom service consulting

隐藏域元素占位

  • 产品描述
  • 细胞复苏
  • 细胞传代
  • 细胞冻存
  • 抗体验证结果
    • Brand: ELEM粒曼
    • Commodity name: APOE Knockout THP-1 Cell Pool
    • Commodity ID: LM01300130203
    • Gene Symbol: APOE
    • Ensembl ID: ENSG00000130203
    • Uniprot ID: P02649
    • 宿主细胞 / 类型: THP-1/人单核细胞白血病
    • NCBI Gene ID: 348
    • 规格: 1×10^6 cells/ 冻存管
    • 生长培养基: RPMI-1640+10% FBS+0.05mM β-mercaptoethanol+1% P/S
    • 筛选标记: N/A
    • 生长特性: 悬浮细胞
    • 培养条件: 37℃,5% CO2 的培养箱,1/2 到 1/4 传代
    • 倍增时间: ~24-36 hours
    • 参考换液频率: 2-3天换液
    • 支原体检测结果: 阴性
    • 敲除效率(Sanger测序): >70%
    • 蛋白质组验证结果: N/A
    • 抗体货号: 添加中
    • 目标基因介绍: (Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434).||APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:6860692, PubMed:1911868, PubMed:14754908). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:6860692, PubMed:2762297, PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:14754908, PubMed:23620513). Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:6860692, PubMed:2762297, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:6860692, PubMed:1911868). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:2762297, PubMed:1917954, PubMed:7768901, PubMed:8939961, PubMed:12950167, PubMed:20030366, PubMed:2063194, PubMed:8756331, PubMed:20303980, PubMed:1530612, PubMed:7635945). Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:9395455, PubMed:9488694, PubMed:23676495, PubMed:7635945). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:23676495, PubMed:29516132). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:2762297, PubMed:1917954, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:9395455, PubMed:14754908, PubMed:23620513). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:8939961, PubMed:25173806). APOE in also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). APOE, may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074).
    • 细胞开发路径: 采用CRISPR-RNP方法生成稳定KO Cell Pool;Sanger 测序结果显示KO Cell Pool敲除效率>70%。
    • 应用: 高敲除效率的基因敲除细胞池(KO Cell Pool),特别适用于初步功能分析、复杂疾病模型的开发、精准药物筛选以及广泛的基因发现研究。KO pool能够无需繁琐的单克隆挑选过程,直接应用于多种类型的测定和分析,大幅提升实验效率。
  • 01.  在 37℃水浴中预热完全培养基。
    02.  将冻存管在 37℃水浴中解冻 1-2 分钟。
    03.  将冻存管转移到生物安全柜中,并用 70% 乙醇擦拭表面。
    04.  拧开冻存管管盖,将细胞悬液轻轻转移到含有 9mL 完全培养基的无菌离心管中。
    05.  在室温下以 125g 离心 5-7 分钟,弃上清。
    06.  用 5mL 的完整培养基重悬细胞沉淀,将细胞悬液转移到 T25 培养瓶中。
    07.  将细胞转移到 37℃,5% CO2 的培养箱中培养。
    08.  参考传代比例:1/2 到 1/4 传代,2-3 天长满。

  • 01.  取少量细胞悬液进行细胞计数及活力检测,当细胞密度达到1.5x10^6 cells/mL时,可进行细胞传代。
    02.  将培养基从 4℃冰箱中拿出, 置于 37℃水浴中温度接近 37℃时取出并在瓶子表面喷洒 75% 酒精后置于生物安全柜中。

    03.  从培养箱中取出待传代的培养瓶,瓶身喷洒 75% 酒精后置于生物安全柜中。
    04.  取足量细胞加入盛有新鲜培养基的培养瓶中,按需求调整接种比例,并补充培养瓶中完全培养基,T75 加至 13-15mL,T25 加至 5mL。将细胞密度维持在7x10^5 cells/mL。
    05.  盖上瓶盖拧紧后轻轻晃动瓶身,使细胞混合均匀后置于 37℃,5% CO2 培养箱中。

  • 01.  准备冻存液,并提前预冷。
    02.  确保待冻存的细胞满足冻存要求,用显微镜检查以下状态:健康的外观及形态特征、所处生 长周期(对数晚期)、无污染或衰退迹象。
    03.  将细胞收集到无菌的锥形离心管中并计数细胞。
    04.  在室温下以250×g离心细胞5分钟,并小心吸出培养基。
    05.  将细胞以至少2x106细胞/mL的密度重悬于冻存液中。
    06.  吹打均匀后按照每管 1mL 的量分装至冻存管。
    07. 将细胞放在程序降温盒中,在 -80℃冰箱中冷冻。
    08. 后续将细胞转移到液氮罐中,以便长期储存。

  • 抗体验证中

Classification: Gene Knockout Cell Pool(KO Pool)

Cell Line Information

Gene Symbol

APOE

NCBI Gene ID

348

Ensembl ID

ENSG00000130203

Uniprot ID

P02649

Screening marker

N/A

Host cell/type

THP-1/人单核细胞白血病

Specifications

1×10^6 cells/ 冻存管

Growth Medium

RPMI-1640+10% FBS+0.05mM β-mercaptoethanol+1% P/S

growth characteristics

悬浮细胞

culture condition

37℃,5% CO2 的培养箱,1/2 到 1/4 传代

doubling time

~24-36 hours

Reference fluid change frequency

2-3天换液

Mycoplasma test results

阴性

Knock-out validation

Knockout efficiency (Sanger sequencing)

>70%

Proteome Validation Results

N/A

Antibody number

添加中

Antibody validation results

抗体验证中

Cell Line Description

Introduction of target gene

(Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434).||APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:6860692, PubMed:1911868, PubMed:14754908). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:6860692, PubMed:2762297, PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:14754908, PubMed:23620513). Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:6860692, PubMed:2762297, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:6860692, PubMed:1911868). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:2762297, PubMed:1917954, PubMed:7768901, PubMed:8939961, PubMed:12950167, PubMed:20030366, PubMed:2063194, PubMed:8756331, PubMed:20303980, PubMed:1530612, PubMed:7635945). Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:9395455, PubMed:9488694, PubMed:23676495, PubMed:7635945). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:23676495, PubMed:29516132). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:2762297, PubMed:1917954, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:9395455, PubMed:14754908, PubMed:23620513). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:8939961, PubMed:25173806). APOE in also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). APOE, may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074).

Cell development path

采用CRISPR-RNP方法生成稳定KO Cell Pool;Sanger 测序结果显示KO Cell Pool敲除效率>70%。

Application

高敲除效率的基因敲除细胞池(KO Cell Pool),特别适用于初步功能分析、复杂疾病模型的开发、精准药物筛选以及广泛的基因发现研究。KO pool能够无需繁琐的单克隆挑选过程,直接应用于多种类型的测定和分析,大幅提升实验效率。

Cell Culture Instructions

Cell Resuscitation

01.  在 37℃水浴中预热完全培养基。
02.  将冻存管在 37℃水浴中解冻 1-2 分钟。
03.  将冻存管转移到生物安全柜中,并用 70% 乙醇擦拭表面。
04.  拧开冻存管管盖,将细胞悬液轻轻转移到含有 9mL 完全培养基的无菌离心管中。
05.  在室温下以 125g 离心 5-7 分钟,弃上清。
06.  用 5mL 的完整培养基重悬细胞沉淀,将细胞悬液转移到 T25 培养瓶中。
07.  将细胞转移到 37℃,5% CO2 的培养箱中培养。
08.  参考传代比例:1/2 到 1/4 传代,2-3 天长满。

cell passage

01.  取少量细胞悬液进行细胞计数及活力检测,当细胞密度达到1.5x10^6 cells/mL时,可进行细胞传代。
02.  将培养基从 4℃冰箱中拿出, 置于 37℃水浴中温度接近 37℃时取出并在瓶子表面喷洒 75% 酒精后置于生物安全柜中。

03.  从培养箱中取出待传代的培养瓶,瓶身喷洒 75% 酒精后置于生物安全柜中。
04.  取足量细胞加入盛有新鲜培养基的培养瓶中,按需求调整接种比例,并补充培养瓶中完全培养基,T75 加至 13-15mL,T25 加至 5mL。将细胞密度维持在7x10^5 cells/mL。
05.  盖上瓶盖拧紧后轻轻晃动瓶身,使细胞混合均匀后置于 37℃,5% CO2 培养箱中。

cell cryopreservation

01.  准备冻存液,并提前预冷。
02.  确保待冻存的细胞满足冻存要求,用显微镜检查以下状态:健康的外观及形态特征、所处生 长周期(对数晚期)、无污染或衰退迹象。
03.  将细胞收集到无菌的锥形离心管中并计数细胞。
04.  在室温下以250×g离心细胞5分钟,并小心吸出培养基。
05.  将细胞以至少2x106细胞/mL的密度重悬于冻存液中。
06.  吹打均匀后按照每管 1mL 的量分装至冻存管。
07. 将细胞放在程序降温盒中,在 -80℃冰箱中冷冻。
08. 后续将细胞转移到液氮罐中,以便长期储存。